Abivax SA filings document the formal U.S. disclosure record of a France-based foreign private issuer and clinical-stage biotechnology company. Form 6-K reports cover current-event disclosures, annual meeting materials, shareholder voting matters, financial results, clinical and regulatory updates for obefazimod, and material agreements tied to the company’s capital structure.
The filing record also includes annual reporting on Form 20-F and references to Form F-3 and Form S-8 registration statements. These documents disclose Abivax’s research-and-development business, ADS and ordinary-share structure, financing activity, governance matters, risk factors, and regulatory reporting obligations in the United States.
Venrock-affiliated funds filed Amendment No. 2 to Schedule 13G reporting a passive stake in Abivax SA (ABVX). The group reported beneficial ownership of 576,729 ordinary shares in the form of ADSs, representing 0.8% of the class as of September 30, 2025.
The holdings comprise 151,622 ADSs by VHCP III, 15,167 ADSs by VHCP Co-Investment III, and 409,940 ADSs by VHCP EG. Each ADS represents one ordinary share. The percentage was calculated against 73,574,749 ordinary shares outstanding as of July 28, 2025, per the issuer’s prospectus supplement. The reporting persons disclose shared voting and dispositive power over 576,729 shares and no sole power. They certified the securities were not acquired to change or influence control.
Abivax SA (ABVX): Schedule 13G/A filed reporting passive ownership by TCG Crossover affiliates and Chen Yu. The filing lists 7,111,596 Abivax ADSs beneficially owned by Chen Yu, equal to 9.1% of the ordinary shares. TCG Crossover Fund I holds 6,456,596 ADSs (8.3%), and TCG Crossover Fund II holds 655,000 ADSs (0.8%).
Each ADS represents one ordinary share. Percentages are based on 77,830,067 ordinary shares outstanding as of September 30, 2025. The reporting persons disclaim group status and certify the securities were not acquired to change or influence control.
Abivax SA (ABVX) — Schedule 13D/A Amendment No. 3: Sofinnova Crossover I SLP and affiliated reporting persons updated their ownership and disclosed recent open‑market sales of American Depositary Shares. As of September 30, 2025, they report holding 4,334,739 Ordinary Shares, representing approximately 5.6% of shares outstanding, and 8,399,478 voting rights, representing approximately 9.4% of voting rights. The base figures cited are 77,830,067 Ordinary Shares and 89,189,666 voting rights outstanding as of September 30, 2025.
The filing lists sales completed in multiple transactions: on October 28, 2025, 522,948 ADSs at a weighted average price of $94.00 per share and 67,929 ADSs at a weighted average price of $95.42; on October 29, 2025, 606,293 ADSs at a weighted average price of $94.00 and 2,830 ADSs at a weighted average price of $95.34. The reporting persons state the shares were acquired for investment purposes and reserve the right to buy or sell as permitted by law.
ABVX: A stockholder filed a Form 144 to sell up to 1,200,000 ADS, with an aggregate market value of $111,300,000. The proposed sale is listed for approximately 10/28/2025 through Leerink Partners on the NASDAQ.
The securities were acquired in the IPO on 10/20/2023, with 1,200,000 ADS purchased from the issuer and paid in cash on 10/24/2023. Shares outstanding were 77,800,000; this is a baseline figure, not the amount being offered.
Abivax SA reported interim results and updates through June 30, 2025 and subsequent events through August 2025. The company completed enrollment in its Phase 3 ABTECT program for ulcerative colitis on April 29, 2025 and announced positive July 22, 2025 induction results: the 50 mg once-daily dose met the FDA primary endpoint of clinical remission at Week 8 with placebo-adjusted rates of 19.3% (ABTECT-1, p<0.0001) and 13.4% (ABTECT-2, p=0.0001). For the six months ended June 30, 2025, R&D expenses rose to €77.9 million (up 21% vs prior year) driven by clinical progression; net financial loss was impacted by €6.9 million interest, €2.3 million FX losses and other non-cash items. Cash and cash equivalents were €60.9 million at June 30, 2025. A July 28, 2025 offering generated gross proceeds of €637.5 million (≈$747.5M) with estimated net proceeds ≈€597.2 million, which management expects, together with existing cash and note conversions, to fund operations into Q4 2027 and provide 12 months of runway after a planned NDA submission, assuming positive maintenance results. The statements were prepared on a going concern basis; shareholders' equity was negative at €48.3 million as of June 30, 2025. The company disclosed conversions of convertible instruments and potential material fair-value impacts in subsequent periods.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report joint beneficial ownership of 3,480,144 Abivax SA ordinary shares (represented by American Depository Shares), equal to 4.78% of the outstanding class. The filing shows 0 shares of sole voting or dispositive power and 3,480,144 shares of shared voting and dispositive power, with the percentage calculated from 72,784,660 ordinary shares outstanding per the issuer's disclosure.
The reporting persons state the securities were not acquired to change or influence control of the issuer (other than activities solely in connection with a nomination under applicable rules). The statement is filed jointly by the two Deep Track entities and David Kroin.